Dysport abobotulinumtoxinA logo

This site is intended for US residents only

Go to Patient Site
Go to Patient Site

This site is intended for US Healthcare Professionals

Dysport abobotulinumtoxinA logo
Pediatric Spasticity Efficacy

What would less frequent injections mean to your patients?

When stiffness returns too early, the struggle resumes... Use Dysport for symptom* relief that lasts between injections.
*Symptoms of spasticity can include abnormal increase in muscle tone and muscle spasm.

Get Dysport Training

When efficacy wears off, even something as simple as getting out of the car can become a challenge again.

When efficacy wears off, even something as simple as getting out of the car can become a challenge again.

IPSE

Patient experience

Annika talking about lower limb spasticity: “Your muscles get tight, your hips pop. It makes it harder to run … Getting in and out of the car can be difficult. It makes running and playing harder, it slows me down.”
Annika’s experience between injections of Dysport: “[After treatment] she starts walking better, as in tripping less. Then slowly she starts tightening up again and luckily it’s time to go back in before it gets unmanageable. [Injection works for] about 3-4 months.” Wendi

A History of FDA Approval

Duration of FDA approval is not intended to imply superiority in efficacy or safety of Dysport

Commitment to spasticity

Dysport has been available for 10+ years in the US and it has been FDA approved for the treatment of AULS since 2015 and for ALLS since 2017.

2009

Dysport approved for cervical dystonia

2015

Dysport approved for adult upper limb spasticity

2016

Dysport approved for pediatric lower limb spasticity

2017

Dysport approved for expanded indication for adult spasticity to include lower limb

2019

Dysport approved for expanded indication for pediatric spasticity to include upper limb (aged 2 years and older)

Efficacy-PULS

Dysport has an established efficacy in reducing muscle tone in pediatric patients with upper limb spasticity at week 6, and improvement could last beyond the minimum retreatment period1

In the treatment of pediatric patients (aged 2 years and older) with spasticity, start Dysport for lasting symptom relief1

The majority of patients in the clinical study were retreated between 16 and 28 weeks; however, some had a longer duration of response1,2
Dysport is FDA approved for the treatment of spasticity in children aged 2 years and older

Study Design1,2

The efficacy and safety of Dysport were evaluated in a randomized, prospective, double-blind, multicenter, phase III, low-dose controlled, multiple treatment study with pediatric patients aged 2 to 17 years with upper limb spasticity.

The primary efficacy endpoint was mean change from baseline in muscle tone by Modified Ashworth Scale (MAS) in the primary targeted muscle group (PTMG) at week 6. Secondary efficacy endpoints were mean change in the Physician’s Global Assessment (PGA) at week 6, and mean Goal Attainment Scale (GAS) score at week 6.

Patients were randomized to receive Dysport 2 Units/kg (n=70), 8 Units/kg (n=70), or 16 Units/kg (n=70) for the first treatment cycle. The completion of 1 cycle occurred when the patient received their next injection. Patients were assessed for retreatment eligibility at week 16. If ineligible for retreatment, they were evaluated every 6 weeks (plus or minus 2 weeks) until eligible. There had to be a minimum of 16 weeks between each injection session, and patients could receive a maximum of 4 sessions over the course of the study. After completing their first treatment cycle, patients receiving Dysport 2 Units/kg were rerandomized to receive Dysport 8 Units/kg or 16 Units/kg. Patients receiving the higher doses remained at their dose unless an adjustment up (not exceeding 16 Units/kg) or down was mandated by the investigator. The study remained double blind for the remaining 3 cycles, or until patients exited the study at 1 year and 9 months.

Study Design

Established efficacy

  • Recommended maximum total dose per treatment session produced statistically significant results vs low-dose Dysport1,2
  • High-Dose Dysport significantly loosened muscles at week 61
Efficient

CI=confidence interval; ITT=intent-to-treat; LS=least squares; MAS=Modified Ashworth Scale

Although week 16 analysis was prespecified, being a tertiary endpoint, appropriate multiplicity adjustments were not applied; therefore, the results need cautious interpretation and could represent chance findings.

At week 6, patients receiving 16 Units/kg demonstrated a 35% greater reduction in muscle tone than those receiving 2 Units/kg

The most frequently reported adverse reactions (≥10%) were upper respiratory tract infection and pharyngitis

Time to retreatment

The effect of Dysport lasted beyond the minimum 16-week retreatment period in some pediatric patients; a majority of patients did not need retreatment until week 22 and effects lasted even after week 34 in some patients.2,*

time to treatment

Time to retreatment was not a primary endpoint. Retreatment for upper limb spasticity should occur no sooner than 16 weeks after the first injection1

Out of the patients receiving Dysport 8 Units/kg, 15.8% were retreated between weeks 34 and 52. Of that number, 3 patients were withdrawn, while 6 did not need a reinjection, or data were missing2

Out of the patients receiving Dysport 16 Units/kg, 20% were retreated between weeks 34 and 52. Of that number, 3 patients were withdrawn, while 7 did not need a reinjection, or data were missing2

The optimal dose of Dysport, muscles to be injected, and retreatment eligibility should be selected based on the patient’s progress and response to treatment1,2

Eligibility for retreatment was assessed by the investigator at every visit onward from week 16 for upper limb spasticity2

*Patients who remained in the upper limb study after week 16 were permitted additional discretionary follow-up visits at week 22, week 28, week 34, or beyond3

Efficacy-PLLS

Dysport has an established efficacy in reducing muscle tone in pediatric patients with lower limb spasticity at week 4, and improvement could last beyond the minimum retreatment period1

In the treatment of pediatric patients (aged ≥2 years) with spasticity, start Dysport for lasting symptom relief1
The majority of patients in the clinical study were retreated between 16 and 22 weeks; however, some had a longer duration of treatment
Dysport is FDA approved for the treatment of spasticity in children aged 2 years and older

Study design1,2

The efficacy and safety of Dysport were evaluated in a multicenter, prospective, double-blind, randomized, placebo-controlled study assessing Dysport in pediatric patients aged 2 to 17 years with lower limb spasticity causing dynamic equinus foot deformity.

The co-primary efficacy endpoints were the reduction in ankle plantar flexor muscle tone at week 4, as measured by the mean change from baseline in Modified Ashworth Scale (MAS*) score and the improvement in response to treatment at week 4, as measured by mean Physician’s Global Assessment (PGA**) of response to treatment score.

Time to retreatment was not the primary endpoint

PGA and MAS were assessed by separate investigators2

*The MAS is an updated version of the Ashworth Scale used to measure muscle tone and includes an additional scoring component to measure resistance during movement.6

**The PGA is a global assessment of a physician’s impression of a patient’s response to treatment.2

clinical Study

*The ITT population (N=235) included all randomized subjects who received at least one injection of study treatment and who had a MAS score in the gastroc-soleus muscle complex assessed both at baseline and at week 4.

In the pivotal clinical trial, doses of Dysport 10 Units/kg/leg or Dysport 15 Units/kg/leg or placebo were injected intramuscularly into the gastrocnemius and soleus muscles1

The 12-week follow-up visit included assessment for retreatment eligibility

Pediatric patients who remained in the study after week 12 were permitted additional discretionary follow-up visits at week 16, week 22, and week 28 to assess eligibility for retreatment6

Established efficacy

  • Dysport significantly reduced muscle tone at week 4 compared to placebo1

Reduction in ankle plantar flexor muscle tone vs placebo as assessed by the mean change in Modified Ashworth Scale (MAS) at week 41

Reduction

CI=confidence interval; ITT=intent-to-treat; LS=least squares; MAS=Modified Ashworth Scale

MAS score at baseline (mean [SD]): placebo, 3.2 (+/–0.4); Dysport 10 Units/kg/leg, 3.1 (+/–0.3); Dysport 15 Units/kg/leg, 3.1 (+/–0.3)1,2

  • Physicians noted a significant response to treatment in patients receiving Dysport at week 41

Dysport had significantly greater response to retreatment vs placebo as assessed by the mean PGA at week 4 (co-primary endpoint) and week 12 (tertiary endpoint)3

The most frequently reported adverse reactions (≥10%) were nasopharyngitis, cough, and pyrexia

Response to treatment vs placebo as assessed by the mean Physician’s Global Assessment (PGA) at week 4 and week 121 

time to treatment

ITT=intent-to-treat; LS-least squares; PGA=Physician’s Global Assessment.

Children on Dysport had a significantly greater response to treatment as assessed by PGA at week 4 (co-primary endpoint) and week 12 (tertiary endpoint)1

Time to retreatment

The effect of Dysport lasted beyond the minimum 12-week retreatment period; most pediatric patients did not need retreatment until week 16 and effects lasted even after week 28 in some patients.1,2,*

time to treatment

Time to retreatment was not a primary endpoint. Repeat Dysport treatment should be administered no sooner than 12 weeks after the previous injection1

*Pediatric patients who remained in the study after week 12 were permitted additional discretionary follow-up visits at week 16, week 22, and week 28 to assess eligibility for retreatment.6

‡4.4% of pediatric patients were retreated after week 28.2

The degree and pattern of muscle spasticity and the overall clinical benefit at the time of reinjection may necessitate alterations in the dose of Dysport (abobotulinumtoxinA) and muscles to be injected1

Eligibility for retreatment was assessed by the investigator at every visit from week 12 onwards

Register

Interested in adding your practice to our Dysport Doctor Locator directory or updating your listing?

Register for Doctor Locator when you sign up for C.L.I.M.B.®

See eligibility criteria at www.CLIMB-training.com

Sign Up Now

The C.L.I.M.B. educational

Learn more about Pediatric Spasticity

Support Dosing & Dilution Safety

IMPORTANT SAFETY INFORMATION

Warning: Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

 

Contraindications

Dysport is contraindicated in patients with known hypersensitivity to any botulinum toxin products, cow’s milk protein, components in the formulation or infection at the injection site(s). Serious hypersensitivity reactions including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea have been reported. If such a reaction occurs, discontinue Dysport and institute appropriate medical therapy immediately.

Warnings and Precautions

Lack of Interchangeability Between Botulinum Toxin Products

The potency Units of Dysport are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products, and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Dysphagia and Breathing Difficulties

Treatment with Dysport and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant side effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of Dysport.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Intradermal Immune Reaction

The possibility of an immune reaction when injected intradermally is unknown. The safety of Dysport for the treatment of hyperhidrosis has not been established. Dysport is approved only for intramuscular injection.

Most Common Adverse Reactions

Adults with lower limb spasticity (≥5%): falls, muscular weakness, and pain in extremity and with upper limb spasticity (≥4%): muscular weakness.

Pediatric patients with lower limb spasticity (≥10%): nasopharyngitis, cough and pyrexia and with upper limb spasticity (≥10%): upper respiratory tract infection and pharyngitis.

Adults with cervical dystonia (≥5%): muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.

Drug Interactions

Co-administration of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of Dysport may potentiate systemic anticholinergic effects, such as blurred vision. The effect of administering different botulinum neurotoxins at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of Dysport.

Special Populations

Use in Pregnancy

There are no adequate and well-controlled studies in pregnant women. Dysport should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Based on animal data, Dysport may cause fetal harm.

Pediatric Use

The safety and effectiveness of Dysport injected into proximal muscles of the lower limb for the treatment of spasticity in pediatric patients has not been established. Based on animal data Dysport may cause atrophy of injected and adjacent muscles; decreased bone growth, length, and mineral content; delayed sexual maturation; and decreased fertility.

Geriatric Use

In general, elderly patients should be observed to evaluate their tolerability of Dysport, due to the greater frequency of concomitant disease and other drug therapy. Subjects aged 65 years and over who were treated with Dysport for lower limb spasticity reported a greater percentage of fall and asthenia as compared to those younger (10% vs. 6% and 4% vs. 2%, respectively).

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Ipsen at 1-855-463-5127. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS

Dysport® (abobotulinumtoxinA) for injection is indicated for the treatment of:

  • Spasticity in patients 2 years of age and older
  • Cervical dystonia in adults

 

Please see full Prescribing Information, including Boxed Warning and Medication Guide.

 

REFERENCES
  1. Dysport® (abobotulinumtoxinA) [Prescribing Information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc; July 2020.
  2. Data on file. Cambridge, MA; Ipsen Biopharmaceuticals, Inc.
  3. Differential diagnosis for spasticity. NeuroRehabResource.org website. http://www.neurorehabresource.org/Files/NRR_Differential_Diagnosis.pdf. Accessed April 6, 2021.
  4. Esquenazi A, Alfaro A, Ayyoub Z, et al. OnabotulinumtoxinA for lower limb spasticity: Guidance from a Delphi Panel approach. PM R. 2017;9(10):960-968.
  5. Barnes M, Kocer S, Fernandez MM, et al. An international survey of patients living with spasticity. Disabil Rehabil. 2017;39(14):1428-1434.
  6. Delgado MR, Tilton A, Russman B, et al. AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: a randomized controlled trial. Pediatrics. 2016;137(2): doi: 10.1542/peds.2015-2830.
  7. Blitzer E, Benson BE, Guss J. Botulinum Neurotoxin for Head and Neck Disorders. New York, NY. Thieme Medical Publishers, Inc. 2012.
  8. Delgado MR, Tilton A, Carranza-del Rio J, et al. Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat-treatment study. Dev Med Child Neurol. 2021;63(5):592-600.
  9. Gracies JM, Brashear A, Jech R, et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015;14(10):992-1001.
  10. Gracies JM, Esquenazi A, Brashear A, et al. Efficacy and safety of abobotulinumtoxinA in spastic lower limb. Neurology. 2017;89(22):2245-2253
  11. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16:316-323.
  12. Truong D, Duane D, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783-791.
Ipsen Logo Ipsen Corporate

© Ipsen Group 2019

Ipsen Logo Ipsen Corporate

© Ipsen Group 2019

Dysport® (abobotulinumtoxinA) for injection, for intramuscular use 300- and 500-Unit vials.
DYSPORT and C.L.I.M.B. are registered trademarks of Ipsen Biopharm Limited.
IPSEN CARES is a registered trademark of Ipsen S.A.

© 2021 Ipsen Biopharmaceuticals Inc. All rights reserved. April 2021 DYS-US-005760